drugset / Trial / NCT05598853
Intrathecal Double Checkpoint Inhibition
NaSingle-groupOpen-labelTreatment
Summary
The objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small cell lung cancer without driver mutation or melanoma.
Timeline
- Start
- 2022-11-25
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intrathecal |
| Subject | Nivolumab | Monoclonal antibody | — | Intrathecal |